GENE ONLINE|News &
Opinion
Blog

2021-06-18| Asia-PacificCOVID-19

South Korea Seeks Global Partners for Upping COVID-19 Vaccine Production

by Kathy Huang
Share To

After the cooperation between Samsung Biologics and Moderna on mRNA vaccine manufacturing, South Korea continues to march forward with the global mRNA vaccine business. 

On June 15th, President Moon Jae-in held a video conference with the CEO of CureVac, Franz-Werner Haas, to request a vaccine partnership.

 

CureVac’s COVID-19 Vaccine Flops

Moderna’s mRNA-1273 and Pfizer-BioNTech’s BNT162b2 are the only two mRNA vaccines approved by FDA. In addition to that, German company CureVac had proposed a third mRNA vaccine candidate, CVnCoV. Yet, the results of the late-stage clinical trial have turned out to be disappointing.

On June 16th, CureVac announced that the efficacy of CVnCoV was just 47%. The result might be among the lowest efficacy of other COVID-19 vaccines so far. The trial had recruited about 40,000 volunteers in Latin America and Europe. However, according to the CEO of CureVac, the final analysis for new COVID-19 cases will continue in the following weeks, probably changing the overall vaccine efficacy positively.

 

Novavax – A Potential Partner for Korea

On the other hand, Novavax has struck gold. On June 14th, the Maryland-based vaccine maker announced that its COVID-19 vaccine, NVX-CoV2373, was more than 90% effective, and its vaccine will be produced by Korea’s SK Bioscience. Novavax has also agreed to deliver 40 million doses of vaccine to South Korea. 

South Korea is tackling a new outbreak of domestic cases, with the infected cases bouncing back to over 500 this week. So far, South Korea has administered at least 15 million doses of COVID-19 vaccines, and almost 25% of its population has received at least one dose.

Related Article: Monoclonal Antibodies for COVID-19: AstraZeneca and Regeneron’s Therapies Endure Contrasting Fortunes

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Sanofi Secures FDA Fast Track Designation for its Chlamydia Prevention mRNA Vaccine
2025-03-27
Controversy Surrounds Jay Bhattacharya’s Nomination as NIH Director
2025-03-05
LATEST
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
Roche Announces Massive 50 Billion Dollar Investment in the United States
2025-04-25
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
2025-04-24
Arkansas Medicaid Work Requirements Led to Coverage Loss for a Significant Number of Recipients
2025-04-24
Boehringer agrees new partnership to advance first-in-class precision cancer therapies
2025-04-24
Bristol Myers Squibb Schizophrenia Drug Fails Pivotal Test as an Add-On to Antipsychotics
2025-04-24
EVENT
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
Scroll to Top